A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan
The REVLIMID Registry is a prospective, multi-center, observational study. The registry will
register 100 patients being prescribed REVLIMID in Taiwan during and patients will be
followed for two years after the enrollment of the last patient.
Safety and efficacy data will be recorded in the registry monthly or bi-monthly. In
accordance with the Risk Minimization Program for REVLIMID (RevAssure) a patient categorized
as a woman of childbearing potential will be prescribed REVLIMID on a monthly basis, whereas
women of non-childbearing potential and men will be allowed up to two months supply per
prescription.
After entry of baseline data, the prescribing physician should prescribe and monitor
REVLIMID therapy according to the guidance and recommended schedules given in the approved
Taiwan package insert (PI)
Observational [Patient Registry]
Observational Model: Case-Only, Time Perspective: Prospective
Adverse Events
Number of participants with adverse events
Up to two years
Yes
Ye Hua, MD
Study Director
Celgene Corporation
Taiwan : Food and Drug Administration
T-CC-5013-MM-009
NCT01752075
January 2011
September 2013
Name | Location |
---|